Two previously unknown dihydro-β-agarofuran sesquiterpenoids, denhaminol I (1) and denhaminol J (2), together with four related and known metabolites, 1α,2α,6β,15-tetraacetoxy-9α-benzoyloxy-8-oxodihydro-β-agarofuran (3), wilforsinine F (4), 1α,2α,6β,8α,15-pentaacetoxy-9α-benzoyloxydihydro-β-agarofuran (5), and 1α,2α,6β,15-tetraacetoxy-9β-benzoyloxydihydro-βagarofuran (6), were isolated from the leaves of the Australian rainforest plant, Denhamia pittosporoides. The structures of 1 and 2 were determined by analysis of 1D/2D NMR and MS data. The absolute configuration of 1 was established by a single-crystal X-ray diffraction experiment. Compounds 1 and 4 were shown to inhibit leucine transport in the human prostate cancer cell line, LNCaP with IC50 values of 51.5 and 95.5 µM, respectively. Both 1 and 4 were more potent than the L-type amino acid transporter (LAT) family inhibitor, 2-aminobicyclo[2.2.
Despite Denhamia (Celastraceae) being an endemic Australian rainforest genus consisting of ten species, [8] there is a paucity of chemical investigations with only two phytochemical studies to date. [9] Denhamia pittosporoides, also known as "orange boxwood" grows as a shrub or tree up to 7 m tall in eastern Queensland and northeastern New South Wales. [8, 10] Previous phytochemical investigation undertaken on the bark of this species led to the isolation of the triterpenoid quinone methide, pristimerin. [9b] In addition, a recent chemical study of the leaves of D. celastroides yielded eight new dihydro-βagarofurans, denhaminols A-H. [9a] As part of our ongoing interest in dihydro-β-agarofurans from Australian Celastraceae species, [7b, 9a, 11] a chemical investigation was conducted on the leaves of D. pittosporoides. This paper reports the isolation and characterization of two new dihydro-β-agarofurans from the leaves of this plant.
The CH2Cl2 extract of the air-dried and ground leaves of D. pittosporoides was subjected to extensive chromatography to afford two new dihydro-β-agarofurans, denhaminols I (1) and J (2) , as well as four known compounds, 1α,2α,6β,15tetraacetoxy-9α-benzoyloxy-8-oxodihydro-β-agarofuran (3), wilforsinine F (4), 1α,2α,6β,8α,15-pentaacetoxy-9αbenzoyloxydihydro-β-agarofuran (5) , and 1α,2α,6β,15tetraacetoxy-9β-benzoyloxydihydro-β-agarofuran (6) (Figure 1) . OR Table 2 ) and edited HSQC spectra of compound 1 displayed the signals for 28 carbon atoms that were attributed to six methyl, two methylene, 11 methine, and nine nonprotonated carbon atoms. A ketone 13 C NMR signal was observed at δC 198.2, while the signals at δC 165.3, 169.2, 169.7, and 170.6 indicated the presence of four ester groups in 1. These data suggested that 1 belonged to the dihydro-βagarofuran structure class. [7b, 11] The COSY spectrum of 1 established the partial structures of H-1/H-2/H2-3/H/4/H3-13 and H-6/H-7 (Figure 2) . The ketone moiety was positioned at C-8 based on HMBC correlations from H-6 (δH 6.45), H-7 (δH 3.09), and H-9 (δH 5.87) to the ketone carbon signal at δC 198.2. Similarly, the positioning of the ester groups in 1 was determined following analysis of HMBC data (Figure 2 ). An HMBC correlation from H-9 (δH 5.87) to an ester carbonyl carbon at δC 165.3 located the benzoate group at C-9, whereas the attachment of three acetoxy moieties was assigned by HMBC correlations from H-1 (δH 5.65), H-6 (δH 6.45), and H2-15 (δH 4.78/5.05) to carbonyl carbons at δC 169.7, 169.2, and 170.6, respectively. Finally, a hydroxy group was attached at C-2 by considering the molecular formula of 1 and the downfield resonances of CH-2 (δH 4.15 and δC 69.4). The relative configuration of 1 was established on the basis of the ROESY data (Figure 2 ) and 1 H-1 H coupling constants. The β-orientation of H-1 and H-2 was indicated by the coupling constant between H-1 and H-2 (J1,2 = 3.0 Hz), while the ROESY spectrum of 1 showed correlations between H-1 and H-8, indicating that these two protons were coplanar. In addition, ROESY correlations between H-6 and H3-14 as well as between H-6 and H2-15 indicated that H-6, CH3-14 and CH2-15 all had αorientations. The absolute configuration of 1 was defined by a single-crystal X-ray diffraction analysis using a CuKα source and unequivocally confirmed the structure of 1 as (1R,2S,4R,5S,6R,7R,9S,10S)-1,6,15-triacetoxy-9-benzoyloxy-2hydroxy-8-oxodihydro-β-agarofuran. An ORTEP drawing of denhaminol I (1) is shown in in Figure 3 . Denhaminol J (2) was isolated as a white amorphous powder. The (+)-HRESIMS molecular ion peak at m/z 569.1992 [M+Na] + (calcd for C28H34O11Na, 569.1993) indicated that 2 was an isomer of 1. The 1 H and 13 C NMR spectra of 2 were almost identical with those of 1, indicating that compound 2 had the same dihydro-β-agarofuran scaffold and the same ester functionalities as 1. However, the 1 H resonance of H-6 was shifted upfield from δH 6.45 in 1 to δH 5.28 in 2, supporting the attachment of a hydroxy group at C-6 in 2, rather than an acetoxy moiety. HMBC correlations from both H-2 (δH 5.39) and a methyl singlet at δH 2.12 to an ester carbonyl carbon at δC 169.9 indicated the substitution of an acetoxy functionality at C-2 (Figure 4) . The 2D NMR data further confirmed the positioning of the remaining ester groups in 2. The relative configuration of 2 was shown to be identical to that of 1 following analysis of the ROESY data. On the basis of biogenetic considerations and comparison of chiroptical and spectroscopic data of compounds 1 and 2, the absolute configuration of 2 was established as (1R,2S,4R,5S,6R,7R,9S,10S)-1,2,15-triacetoxy-9-benzoyloxy-6hydroxy-8-oxodihydro-β-agarofuran. The chemical structures of the known dihydro-β-agarofurans, including 1α,2α,6β,15-tetraacetoxy-9α-benzoyloxy-8-oxodihydroβ-agarofuran (3), [12] wilforsinine F (4), [13] 1α,2α,6β,8α,15pentaacetoxy-9α-benzoyloxydihydro-β-agarofuran (5), [14] and 1α,2α,6β,15-tetraacetoxy-9β-benzoyloxydihydro-β-agarofuran (6) [15] were determined following NMR, MS, and specific rotation data comparison with literature values. In this report, we also include the electronic circular dichroism (ECD) data of the known compounds 3-6, which were not reported in the original publications. Comparison of ECD spectra (see Figure 5 ) and specific rotation data of 1 and 3 indicated that both compounds had the same absolute configuration. Consequently, the structure of 3 was identified as (1R,2S,4R,5S,6R,7R,9S,10S)-1,2,6,15-tetraacetoxy-9-benzoyloxy-8-oxodihydro-β-agarofuran, which is in agreement with the absolute configuration reported in the original paper.
Due to our previous finding on dihydro-β-agarofurans that inhibit leucine uptake, [7b] the major metabolites 1, 3, and 4 were tested for their effect on leucine transport in the androgenresponsive prostate cancer cell line, LNCaP. In a dose response inhibition analysis, compounds 1 and 4 inhibited leucine transport with IC50 values of 51.5 and 95.5 µM, respectively, while compound 3 had little effect on leucine transport (see Figure 6 ). Both compounds 1 and 4 showed leucine transport inhibition that was more potent than the L-type amino acid transporter (LAT) family inhibitor, 2-aminobicyclo[2.2.1]-heptane-2-carboxylic acid (BCH), which had an IC50 value of 4060 µM in LNCaP cells. [16] In LNCaP cells, leucine transport is mainly mediated by LAT3 and is required for prostate cancer growth and progression. [17] Several studies have isolated and purified new leucine transporter inhibitors from plants, such as Pittosporum venulosum and Maytenus bilocularis. [7b, 16, 18] Our study has identified new dihydro-β-agarofurans from D. pittosporoides, which can be used as leucine transporter inhibitors in prostate cancer. All dihydro-β-agarofurans (1) (2) (3) (4) (5) (6) reported in this study have been added to the Davis Open-Access Compound Library, which is housed at Compounds Australia, Griffith University and is a resource that can be accessed for drug discovery and chemical biology research. [19] reduced pressure that was subjected to Si-flash column chromatography (25 × 50 mm) using stepwise n-hexane/EtOAc gradient solvent system (100% n-hexane to 100% EtOAc), to afford 97 fractions (~10 mL each). Similar fractions were combined following TLC analysis (nhexane/EtOAc) to give 15 fractions (F1-F15). Fraction F8 (7.6 mg) was preadsorbed to C18-bonded silica (~1 g), packed into a guard cartridge, and attached to a semipreparative C18 HPLC column. A linear gradient from 60% MeOH (0.1% TFA)/40% H2O (0.1% TFA) to 85% MeOH (0.1% TFA)/15% H2O (0.1% TFA) at a flow rate of 4 mL/min was performed over 60 min to yield 1α,2α,6β,15-tetraacetoxy-9β-benzoyloxydihydro-βagarofuran (6, 1.4 mg, tR 40-41 min, 0.014% dry wt). Fraction F10 (27.9 mg) was preadsorbed to phenyl bonded silica (~1 g), packed into a guard cartridge, and connected to a semipreparative phenyl-hexyl HPLC column. Isocratic conditions of 50% MeOH (0.1% TFA)/50% H2O (0.1% TFA) was initially employed for 5 min, followed by a linear gradient to 100% MeOH (0.1% TFA) over 45 min, then isocratic 100% MeOH (0.1% TFA) for 10 min, all at a flow rate of 4 mL/min. Sixty fractions (60 × 1 min) were collected from the start of the HPLC run. The fractions eluting at 38-39 min afforded 1α,2α,6β,15-tetraacetoxy-9α-benzoyloxy-8oxodihydro-β-agarofuran (3, 12.4 mg, 0.122% dry wt). Fraction F11 (21.1 mg) was further separated following the same HPLC procedure described above. From this separation, the fraction eluting at 33 min was further purified using a phenyl-hexyl HPLC column with a linear gradient from 60% MeOH (0.1% TFA)/40% H2O (0.1% TFA) to 90% MeOH (0.1% TFA)/10% H2O (0.1% TFA) in 60 min at a flow rate of 4 mL/min to give pure denhaminol I (1, 3.5 mg, tR 28-30 min, 0.035 % dry wt), while the fraction eluting at 39 min was subjected to semipreparative C18 HPLC using a linear gradient from 60% MeOH (0.1% TFA)/40% H2O (0.1% TFA) to 85% MeOH (0.1% TFA)/15% H2O (0.1% TFA) in 60 min at a flow rate of 4 mL/min to afford 1α,2α,6β,8α,15-pentaacetoxy-9αbenzoyloxydihydro-β-agarofuran (5, 1.6 mg, tR 30, 0.016% dry wt). Fraction F12 (45.9 mg) was separated using the same protocol detailed for the separation of fraction F10. Fractions collected at 31-33 min (35 mg) from this purification step were pooled and subjected to further chromatography using a semipreparative biphenyl HPLC column and a linear gradient from 60% MeOH (0.1% TFA)/40% H2O (0.1% TFA) to 90% MeOH (0.1% TFA)/10% H2O (0.1% TFA) at a flow rate of 4 mL/min in 60 min, which furnished wilforsinine F (4, 4.8 mg, tR 42-44, 0.048% dry wt), semipure denhaminol J (3.7 mg, tR 35 min) and semipure denhaminol I (22.0 mg, tR 36-40 min). The fraction (3.7 mg) eluting at 35 min was further purified using a biphenyl HPLC column and isocratic conditions of 65% MeOH (0.1% TFA)/35% H2O (0.1% TFA) solvent system to give denhaminol J (2, 1.1 mg, tR 23-27, 0.011% dry wt), while the fractions (22.0 mg) eluting between 36-40 min were combined and subjected to semipreparative C18 HPLC with a linear gradient from 60% MeOH (0.1% TFA)/40% H2O (0.1% TFA) to 85% MeOH (0.1% TFA)/15% H2O (0.1% TFA) at a flow rate of 4 mL/min in 60 min to yield more of pure denhaminol I (1, 8.2 mg, tR 22 min, 0.082% dry wt). 
X-Ray Diffraction Analysis.
Intensity data for 1 were collected with an Oxford Diffraction SuperNova CCD diffractometer using Cu-Kα radiation, the temperature during data collection was maintained at 130.0(1) K using an Oxford Cryosystems cooling device. The structure was solved by direct methods and difference Fourier Synthesis. [20] Hydrogen atoms bound to the carbon atom were placed at their idealized positions using appropriate HFIX instructions in SHELXL, and included in subsequent refinement cycles. The hydrogen atom attached to oxygen was located from difference Fourier maps and refined freely with isotropic displacement parameters. Thermal ellipsoid plots were generated using the program ORTEP-3 [21] integrated within the WINGX suite of programs. [22] CCDC 1494636 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/cgi-bin/catreq.cgi. Leucine Transport Inhibition Assay. Human prostate cancer cell line LNCaP was purchased from American Type Culture Collection (Manassas, VA, USA). We confirmed LNCaP cell identity by STR profiling in 2014 (Cellbank, Australia). Cells were cultured in RPMI 1640 medium (Life Technologies, Australia) containing 10% (v/v) fetal bovine serum (FBS), penicillin-streptomycin solution (Sigma-Aldrich, Australia) and 1 mM sodium pyruvate (Life Technologies, Australia). Cells were maintained at 37 °C in a fully humidified atmosphere containing 5% CO2. The [ 3 H]-L-leucine uptake was performed as detailed previously. [17a] Briefly, cells were cultured in 6-well plates in RPMI media. After collecting and counting, cells (3×10 4 /well) were incubated with 0.3 µCi [ 3 H]-Lleucine (200 nM; PerkinElmer) in leucine-free RPMI media (Invitrogen) with 10% (v/v) dialyzed FBS in the presence of different concentrations of compounds for 15 min at 37 °C. Cells were collected, transferred to filter paper using a scintillation mat harvester (PerkinElmer), dried, exposed to scintillation fluid and counts measured using a MicroBeta2 scintillation counter (PerkinElmer). GraphPad Prism 6 was used to determine the IC50 of each compound. Each data point was determined in triplicate, and repeated in three independent experiments.
